INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
← catalyst calendarSponsored by Inovio Pharmaceuticals (industry) · INO — their whole pipeline →.
Phase
Phase 1/2
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
35actual
Sites
11
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-05-24 | actual | When the study began enrolling |
| Primary completion | 2025-05-09 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-09 | actual | The whole study's end, after follow-up |
| First posted | 2018-04-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Urothelial Carcinoma
Interventions
- Biological: INO-5401
- Biological: INO-9012
- Drug: Atezolizumab
- Device: CELLECTRA™ 2000
Primary outcomes
what the primary-completion date above is the date OFNumber of Adverse Events
measured From baseline up to 90 days after last dose of study medication (up to approximately 2 years and 3 months)
Antigen-Specific Cellular Immune Response
measured At baseline, Weeks 3, 6, 9, 12 and every 12 weeks thereafter up to end of study (up to approximately 2 years)
Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator Review in Cohort A
measured From Baseline to disease progression or death, whichever occurs first (up to approximately 2 years)
Permalink · INO's whole pipeline · Catalyst calendar · Every registered study · What changed